For Research Use Only · Not for Human Consumption · Not for therapeutic or diagnostic use
PEPTITAN
← All research notes

Cagrilintide 5mg+Semaglutide 5mg

Cagrilintide (5 mg) + Semaglutide (5 mg) research blend for dual-agonist studies.

Mechanism & research context

Research blend combining 5 mg of cagrilintide and 5 mg of semaglutide in a single vial. Used in combined amylin/GLP-1 receptor-pharmacology research. Supplied as lyophilized powder at ≥98% HPLC purity.

Selected studies

  • "Cagrilintide combined with semaglutide achieved 13.7% weight loss, with 73.5% of patients reaching glycated hemoglobin of 6.5% or less."
    New England Journal of Medicine — CagriSemaView study
  • "Once-weekly semaglutide 2.4 mg produced a mean ~15% body-weight reduction."
    New England Journal of Medicine — STEP-1 trialView study
Use disclaimerFor Research Use Only. Not for Human Consumption. Not a drug, food, or cosmetic.
Article reflects published preclinical and in-vitro literature..
Cagrilintide 5mg+Semaglutide 5mg — Research notes — Peptitan